Momenta prices underwritten public offering

Download PDF Copy

Reviewed

Momenta Pharmaceuticals, Inc.Dec 8 2010

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at $14.35 per share. The total proceeds, before expenses, to Momenta will be approximately $57.4 million. The offering is expected to close on December 13, 2010, subject to customary closing conditions.

UBS Investment Bank is the sole book-running manager for the offering. Cowen and Company and Canaccord Genuity are acting as co-managers for the offering. Momenta has granted the underwriter a 30-day option to purchase up to an additional 600,000 shares of common stock to cover overallotments, if any.

Source:

Momenta Pharmaceuticals, Inc.

Posted in:

Comments (0)

Download PDF Copy

Suggested Reading

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes

Do GLP-1 drugs cause cancer? New review says no, may even protect

Bariatric surgery reshapes body fat and muscle more than GLP-1 drugs

GLP-1 drugs calm inflammation beyond diabetes and weight loss

Diabetes drugs semaglutide and tirzepatide show real-world heart benefits

Diabetes remission possible with GLP-1 drugs, Italian study confirms

Study finds GLP-1 drugs improve strength and reverse aging biology in mice

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.